InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
17,168.35
(
0.63%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.16
(
0.01%
)
Bitcoin
64,357.68
(
-0.20%
)
Post# of 2337616
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

zino

Send PM Follow Ignore
Followers 335
Posts 18989
Boards Moderated 0
Alias Born 08/25/2007

zino

Re: None

Tuesday, 03/28/2017 11:25:04 AM

Tuesday, March 28, 2017 11:25:04 AM

Post# of 2337616
ITUS ... achieved sensitivity of 92% and specificity of 92% for 88 patient samples,
On December 7, 2016, ITUS announced preliminary results from its Cchek™ cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient’s immunological response to a malignancy, the Company achieved sensitivity of 92% and specificity of 92% for 88 patient samples, including 54 samples from patients with multiple types and severities of cancer, and 34 healthy patients.
http://ih.advfn.com/p.php?pid=nmona&article=74109620

DONT LISTEN TO ME IM CANADIANNNNNNNN

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up